Avecia completes sales of its Pharmaceuticals business unit
07-Dec-2005
NPIL has paid GBP 9.5 million in cash for the entire Pharmaceuticals custom synthesis business which will be used to fund the UK pension fund deficit of Avecia Pharmaceuticals Limited.
Most read news
Organizations
Avecia Biologics
Nicholas Piramal
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.